Contineum Therapeutics, Inc. (NASDAQ:CTNM)
| Market Cap | 479.33M+4.2% |
| Revenue (ttm) | 0 |
| Net Income | -57.56M-1.2% |
| EPS | -1.73+21.4% |
| Shares Out | 37.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 284,060.256 |
| Open | 12.55 |
| Previous Close | 12.73 |
| Day's Range | 12.39 - 13.06 |
| 52-Week Range | 8.60 - 17.79 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 21.33(+67.41%) |
| Earnings Date | Oct 29, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CTNM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CTNM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CTNM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CTNM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CTNM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CTNM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CTNM
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $15.95M |
| IWMiShares Russell 2000 ETF | $9.26M |
| VXFVanguard Extended Market ETF | $4.98M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $3.08M |
| IBBiShares Biotechnology ETF | $2.88M |
| VTWOVanguard Russell 2000 ETF | $2.51M |
Estimated from each fund’s disclosed top holdings × AUM
CTNM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CTNM’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score